Eusol Biotech Co.,Ltd. (6652.TWO)
TWD 6.05
(-22.34%)
TWD 6.05
(-22.34%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -43.03 Million | -52.88 Million | -88.88 Million | -89.95 Million | -82.11 Thousand |
| Net Income | -49.12 Million | -12.28 Million | -123.58 Million | -113.49 Million | -107.25 Thousand |
| Depreciation & Amortization | 4.02 Million | 23.19 Million | 28.21 Million | 29.41 Million | 28.59 Thousand |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 554 Thousand | - |
| Change in working capital | -1 Million | -6.84 Million | 4.27 Million | -6.51 Million | 624.00 |
| Other non-cash items | -4.49 Million | -1.72 Million | -506 Thousand | -402 Thousand | -4081.00 |
| Investing Cash Flow | 113.87 Million | -48.62 Million | -30.64 Million | 14.58 Million | -5877.00 |
| Investments in PPE | -112 Thousand | -83 Thousand | -640 Thousand | -1.78 Million | -11.79 Thousand |
| Acquisitions | 1.11 Million | - | - | - | 5.99 Million |
| Investment purchases | - | -220.6 Million | -30 Million | - | - |
| Sales/Maturities of investments | 112.87 Million | - | - | 16.2 Million | - |
| Other Investing Activities | 113.94 Thousand | 422 Thousand | -30.07 Thousand | 16.22 Thousand | 115 Thousand |
| Financing Cash Flow | -2.43 Million | -3.43 Million | 295.21 Million | -4.76 Million | -4750.00 |
| Debt repayment | -2438.00 | -3431.00 | -4783.00 | -4763.00 | -4748.00 |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 300 Million | - | - |
| Other Financing Activities | -2.43 Million | - | 300 Thousand | - | -2000.00 |
| Accounts receivables | -4587.00 | -2357.00 | 13.00 | -1907.00 | 1582.00 |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 5442.00 | 4363.00 | 369.00 | -2676.00 | -958.00 |
| Cash at beginning of period | 144.65 Million | 248.08 Million | 72.82 Million | 153.87 Million | 248.48 Thousand |
| Cash at end of period | 213.69 Million | 144.65 Million | 248.08 Million | 72.82 Million | 153.87 Thousand |
| Capital Expenditure | -112 Thousand | -83 Thousand | -640 Thousand | -1.78 Million | -11.79 Thousand |
| Effect of forex changes on cash | 635 Thousand | 1.51 Million | -435 Thousand | -911 Thousand | -1872.00 |
| Net cash flow / Change in cash | 69.03 Million | -103.42 Million | 175.25 Million | -81.04 Million | -94.61 Thousand |
| Free Cash Flow | -43.14 Million | -52.96 Million | -89.52 Million | -91.74 Million | -93.91 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7863.00 | -7863.00 | -16.72 Thousand | -49.12 Million | -16.72 Thousand | -9084.00 |
| Depreciation & Amortization | 894.50 | 894.50 | 884.50 | 4.02 Million | 884.50 | 1101.50 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 221.50 | 221.50 | 1435.00 | -1 Million | 1435.00 | -1007.50 |
| Other non-cash items | -160.00 | -160.00 | 6367.50 | -4.49 Million | 6367.50 | -4490.00 |
| Investing Cash Flow | 9008.00 | 9008.00 | 53.86 Thousand | 113.87 Million | 53.86 Thousand | 3071.00 |
| Investments in PPE | 14.2 Million | - | -36.00 | -112 Thousand | -36.00 | - |
| Acquisitions | 19 Thousand | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | 18 Million | - | - | 112.87 Million | - | - |
| Other Investing Activities | 9008.00 | 9008.00 | 53.9 Thousand | 113.94 Thousand | 53.9 Thousand | 3071.00 |
| Financing Cash Flow | -609.50 | -609.50 | -609.50 | -2.43 Million | -609.50 | -609.50 |
| Debt repayment | -387 Thousand | - | - | -2438.00 | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -609.50 | -609.50 | -609.50 | - | -609.50 | -609.50 |
| Accounts receivables | 232.50 | 232.50 | -1047.00 | -4587.00 | -1047.00 | -1246.50 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -11.00 | -11.00 | 2482.00 | 5442.00 | 2482.00 | 239.00 |
| Cash at beginning of period | 213.69 Million | - | - | 144.65 Million | - | - |
| Cash at end of period | 1491.50 | 1491.50 | 45.43 Thousand | 213.69 Million | 45.43 Thousand | -10.91 Thousand |
| Capital Expenditure | 14.2 Million | - | -36.00 | -112 Thousand | -36.00 | - |
| Effect of forex changes on cash | - | - | 212.00 | 635 Thousand | 212.00 | 105.50 |
| Net cash flow / Change in cash | -213.69 Million | 1491.50 | 45.43 Thousand | 69.03 Million | 45.43 Thousand | -10.91 Thousand |
| Free Cash Flow | 14.19 Million | -6907.00 | -8071.50 | -43.14 Million | -8071.50 | -13.48 Thousand |
1966
VEST
2439
MOL
0020
UOG